Four things to know:
1. The company’s net sales were $118.1 million, down 2.7 percent from the same period last year.
2. Spinal implant sales fell 6.2 percent to $28.2 million, and biologic sales fell less than 1 percent, to $14.8 million.
3. All areas of Orthofix’s business except global orthopedics saw year-over-year decreases in revenue. Global orthopedics saw a 2 percent increase in revenue year over year..
4. The company saw gross profits of $86.5 million, down 8 percent year over year.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
